INTRODUCTION {#s1}
============

According to the National Cancer Institute, there were approximately 12,900 new cases diagnosed and 4,100 deaths due to cervix cancer in 2015 \[[@R1]\]. About 90% of cervical cancer patients are squamous cell carcinoma. Small cell carcinoma of the cervix (SCCC) is a rare disease accounting for approximately 2--5% of uterine cervix malignancies \[[@R2]--[@R4]\].

SCCC was first reported by Reagan *et al*. in 1957 \[[@R5]\]. Like small cell carcinoma in other body sites, SCCC is highly invasive and prone to distant metastatic spread \[[@R3], [@R4], [@R6]--[@R8]\], causing poorer prognosis than other types of cervical cancer. The 5-year survival rates vary from 0% to 51% of patients with SCCC \[[@R8]--[@R11]\]. However, the clinicopathological features and biological behavior of SCCC in above studies were including limited number of patients. The aims of this study were to investigate the clinicopathological characteristics and survival in patients with SCCC using Surveillance, Epidemiology, and End Results (SEER) database.

RESULTS {#s2}
=======

Demographic, clinicopathological, and treatment characteristics {#s2_1}
---------------------------------------------------------------

SEER database included 107,618 patients with small cell carcinoma and 65,761 patients with cervix cancer from 1988 to 2012. We included 487 patients with SCCC and a median age of 49 years (range, 19--95 years). The demographic, clinicopathological, and treatment characteristics are depicted in Table [1](#T1){ref-type="table"}. The incidence of SCCC differed significantly according to age group. Patients with ages 40-49 years had a much higher incidence.

###### Patient characteristics

  Variable                        n (%)
  ------------------------------- ----------------
  Age (years)                     
    Median (Range)                49 (19-95)
    19-29                         59 (12.1)
    30-39                         85 (17.5)
    40-49                         115 (23.6)
    50-59                         85 (17.5)
    60-69                         72 (14.8)
    70-79                         47 (9.7)
    80+                           24 (4.8)
  Race                            
    Black                         66 (13.6)
    White                         347 (71.3)
    Other and unknown             74 (15.1)
  Marital status                  
    No                            212 (45.2)
    Yes                           257 (54.8)
    Unknown                       18
  FIGO Stage                      
    IA                            33 (7.2)
    IB                            82 (17.9)
    I NOS                         5 (1.1)
    IIA                           12 (2.6)
    IIB                           28 (6.1)
    IIIA                          10 (2.2)
    IIIB                          113 (24.7)
    III NOS                       1 (0.2)
    IVA                           9 (2.0)
    IVB                           163 (35.7)
    IV NOS                        1 (0.2)
    Unknown                       30
  Grade                           
    Well differentiated           1 (0.3)
    Moderately differentiated     4 (1.2)
    Poorly/undifferentiated       326 (98.5)
    Unknown                       156
  Tumor size                      
    Median size (cm) (range)      5.5 (0.2-21.0)
    ≤4 cm                         95 (34.5)
    \>4 cm                        180 (65.5)
    Unknown                       212
  SEER stage                      
    Localized                     112 (24.2)
    Regional                      180 (39.0)
    Distant                       170 (36.8)
    Unknown                       25
  Local treatment modalities      
    Hysterectomy ± radiotherapy   164 (44.4)
    Radiotherapy                  205 (55.6)
    Unknown                       118
  Lymphadenectomy                 
    No                            325 (68.6)
    Yes                           149 (31.4)
     Node negative                71 (47.7)
     Node positive                78 (52.3)
    Unknown                       13

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; SEER, Surveillance Epidemiology and End Results.

A total of 457 patients with International Federation of Gynecology and Obstetrics (FIGO) stage was available, 120 patients (26.3%) had stage I disease, 40 patients (8.8%) in FIGO stage II, 124 patients (27.1%) in stage III, and 173 patients (37.9%) in stage IV. Of the 331 patients with known histologic grade, 326 (98.5%) had tumors with poorly/undifferentiated grade. According to SEER stage (n = 462), 112 (24.2%) patients had localized stage, 180 (39.0%) had regional stage, and 170 (36.8%) had distant stage. A total of 275 patients with known tumor size, 180 (65.5%) had tumor size \> 4 cm (Table [1](#T1){ref-type="table"}).

Of the 369 patients with known local treatment modalities including hysterectomy and radiotherapy, 74 patients (20.1%) were treated with primary hysterectomy, 90 (24.4%) patients received hysterectomy and radiotherapy, and 205 (55.6%) patients received primary radiotherapy. A total of 149 patients received lymphadenectomy, and 78 (52.3%) of them were node-positive disease (Table [1](#T1){ref-type="table"}).

Survival {#s2_2}
--------

Median survivals along with 5-year cause-specific survival (CSS) and overall survival (OS) for SCCC are summarized in Table [2](#T2){ref-type="table"}. Mortality increased rapidly in the three years following diagnosis. Figure [1A](#F1){ref-type="fig"} shows the CSS of the SCCC patients. The 1-, 3-, 5-, and 10-year CSS was 61.6%, 37.3%, 33.0%, and 22.9%, respectively. The 1-, 3-, 5-, and 10-year OS was 60.4%, 34.7%, 29.4%, and 26.3%, respectively (Figure [1B](#F1){ref-type="fig"}). Patients with younger age, non-black racial status, married status, early stage, localized stage, node-negative tumors, and treatment with surgery ± radiotherapy had better CSS and OS (all *P* \< 0.05). No differences in CSS and OS were observed among tumor grades and tumor size.

###### Median, 5-year cause-specific survival and overall survival

  Variable                            CSS   OS                             
  ----------------------------------- ----- ------ ---------- ----- ------ ----------
  Age(years)                                                               
    19-29                             60    50.2   \< 0.001   57    48.3   \< 0.001
    30-39                             29    40.6              29    40.6   
    40-49                             26    40.1              23    35.9   
    50-59                             19    32.9              18    26.4   
    60-69                             10    16.4              10    14.2   
    70-79                             9     16.0              9     9.0    
    80+                               5     12.5              5     12.5   
  Race                                                                     
    White                             18    32.8   0.032      18    30.4   0.009
    Black                             13    23.2              11    16.9   
    Other and unknown                 29    42.0              27    36.5   
  Marital status                                                           
    No                                16    29.5   0.033      15    25.7   0.011
    Yes                               25    37.7              22    35.0   
  FIGO stage                                                               
    I                                 240   60.7   \< 0.001   125   55.2   \< 0.001
    II                                29    40.3              29    40.3   
    III                               25    31.3              24    28.5   
    IV                                8     12.1              7     9.0    
  Grade                                                                    
    Well/ moderately differentiated   17    20.0   0.581      17    20.0   0.697
    Poorly/undifferentiated           21    34.0              19    30.5   
  Tumor size                                                               
    ≤ 4 cm                            31    37.7   0.101      26    32.7   0.128
    \> 4 cm                           20    35.1              19    32.9   
  SEER stage                                                               
    Localized                         240   60.1   \< 0.001   125   55.0   \< 0.001
    Regional                          26    34.1              25    31.2   
    Distant                           7     12.6              7     9.3    
  Nodal status                                                             
    Node negative                     ---   62.7   0.002      ---   59.5   0.002
    Node positive                     27    38.5              26    35.6   
  Local treatment modalities                                               
    Hysterectomy ± radiotherapy       96    52.0   \< 0.001   57    49.0   \< 0.001
    Radiotherapy                      15    24.0              15    20.1   

Abbreviations: CSS, cause-specific survival; FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; SEER, Surveillance Epidemiology and End Results.

![Cause-specific survival **(A)** and overall survival **(B)** for all patients.](oncotarget-08-40425-g001){#F1}

Prognostic factors {#s2_3}
------------------

Age at diagnosis, race, marital status, SEER stage, FIGO stage, lymph node status, and local treatment modalities were significant prognostic factors for CSS and OS by univariate analysis, whereas tumor size and tumor grade were not (Table [3](#T3){ref-type="table"}).

###### Univariate analysis of cause-specific survival and overall survival

  Variable                            CSS               OS                                                       
  ----------------------------------- ----------------- ------------- ---------- ----------------- ------------- ----------
  Age (years) (continuous variable)   1.024             1.017-1.031   \< 0.001   1.026             1.019-1.033   \< 0.001
  Race                                                                                                           
    White                             1 \[Reference\]                            1 \[Reference\]                 
    Black                             1.351             0.982-1.858   0.064      1.477             1.095-1.993   0.011
    Other                             0.770             0.553-1.071   0.121      0.807             0.590-1.105   0.182
  Marital status                                                                                                 
    No                                1 \[Reference\]                            1 \[Reference\]                 
    Yes                               0.781             0.619-0.984   0.036      0.752             0.601-0.940   0.012
  FIGO stage                                                                                                     
    I                                 1 \[Reference\]                            1 \[Reference\]                 
    II                                1.663             1.011-2.734   0.045      1.492             0.925-2.408   0.101
    III                               2.229             1.549-3.207   \< 0.001   2.087             1.478-2.938   \< 0.001
    IV                                5.522             3.927-7.764   \< 0.001   5.213             3.781-7.187   \< 0.001
  Grade                                                                                                          
    Well/ moderately differentiated   1 \[Reference\]                            1 \[Reference\]                 
    Poorly/undifferentiated           0.760             0.282-2.047   0.588      0.824             0.306-2.218   0.702
  SEER stage                                                                                                     
    Localized                         1 \[Reference\]                            1 \[Reference\]                 
    Regional                          1.999             1.414-2.827   \< 0.001   1.961             1.413-2.722   \< 0.001
    Distant                           5.324             3.767-7.523   \< 0.001   5.153             3.707-7.163   \< 0.001
  Tumor size                                                                                                     
    ≤ 4 cm                            1 \[Reference\]                            1 \[Reference\]                 
    \> 4 cm                           1.312             0.944-1.823   0.106      1.272             0.929-1.740   0.133
  Nodal status                                                                                                   
    Node negative                     1 \[Reference\]                            1 \[Reference\]                 
    Node positive                     2.066             1.278-3.342   0.003      2.050             1.288-3.262   0.002
  Local treatment modalities                                                                                     
    Hysterectomy ± radiotherapy       1 \[Reference\]                            1 \[Reference\]                 
    Radiotherapy                      2.292             1.734-3.209   \< 0.001   2.304             1.765-3.009   \< 0.001

Abbreviations: CI, confidence interval; CSS, cause-specific survival; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; SEER, Surveillance Epidemiology and End Results.

A stepwise multivariable analysis of variables that were significant by univariate analysis showed that increasing age (CSS: hazard ratio \[HR\] 1.016, 95% confidence interval \[CI\] 1.008-1.025, *P* = 0.001; OS: HR 1.019, 95%CI 1.011-1.027, *P* \< 0.001), advanced FIGO stage (CSS: HR 1.579, 95%CI 1.383-1.802, *P* \< 0.001; OS: HR 1.545, 95%CI 1.362-1.752, *P* \<0.001) and treatment by primary radiotherapy (CSS: HR 1.873, 95%CI 1.399-2.508, *P* \< 0.001; OS: HR 1.854, 95%CI 1.402-2.452, *P* \< 0.001) were significantly related to inferior CSS and OS (Table [4](#T4){ref-type="table"}). Figure [2](#F2){ref-type="fig"} shows CSS and OS according to FIGO stage.

###### Multivariate analyses of cause-specific survival and overall survival

  Variable                             CSS     OS                                             
  ------------------------------------ ------- ------------- ---------- ------- ------------- ----------
  **Entire group**                                                                            
   Age (years) (continuous variable)   1.016   1.008-1.025   \< 0.001   1.019   1.011-1.027   \< 0.001
   Race                                ---     ---           ---        0.953   0.794-1.143   0.602
   Marital status                      1.160   0.871-1.545   0.310      1.100   0.835-1.449   0.499
   FIGO stage                          1.579   1.383-1.802   \< 0.001   1.545   1.362-1.752   \< 0.001
   SEER stage                          0.817   0.542-1.620   0.817      0.951   0.564-1.605   0.852
   Local treatment modalities          1.873   1.399-2.508   \< 0.001   1.854   1.402-2.452   \< 0.001
  **With lymphadenectomy**                                                                    
   Age                                 1.007   0.987-1.027   0.517      1.008   0.988-1.028   0.451
   Race                                ---     ---           ---        1.178   0.836-1.659   0.348
   Marital status                      0.818   0.473-1.417   0.476      0.903   0.528-1.546   0.710
   FIGO stage                          1.365   1.060-1.757   0.016      1.316   1.030-1.680   0.028
   SEER stage                          0.548   0.100-2.992   0.487      0.475   0.088-2.579   0.389
   Nodal status                        0.911   0.237-3.497   0.892      0.886   0.232-3.378   0.859
   Adjuvant radiotherapy               1.928   1.081-3.437   0.026      1.942   1.106-3.412   0.021

Abbreviations: CI, confidence interval; CSS, cause-specific survival; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; SEER, Surveillance Epidemiology and End Results.

![Cause-specific survival **(A)** and overall survival **(B)** according to International Federation of Gynaecology and Obstetrics stage.](oncotarget-08-40425-g002){#F2}

We further analyzed the prognostic factors for patients who underwent hysterectomy and lymphadenectomy. As adjusted for age, race, marital status, SEER stage, lymph node status, and local treatment strategies, advanced FIGO stage (CSS: HR 1.365, 95%CI 1.060-1.757, *P* = 0.016; OS: HR 1.316, 95%CI 1.030-1.680, *P* = 0.028) and local treatment modalities (hysterectomy and radiotherapy vs. hysterectomy) (CSS: HR 1.928, 95%CI 1.081-3.437, *P* = 0.026; OS: HR 1.942, 95%CI 1.106-3.412, *P* = 0.021) were still the independent prognostic factors of survival. The lymph node status has no effect on survival outcome in patients received lymphadenectomy.

DISCUSSION {#s3}
==========

Most of the knowledge in the SCCC comes from single-institution reports with a limited numbers of patients \[[@R12]--[@R14]\]. Here, we identified 487 patients of histologically confirmed SCCC between 1988 and 2012 from the SEER registry. Previous studies have showed that SCCC accounts for 2--5% of all cervix cancers \[[@R2]--[@R4]\]. The incidence rate in our study was 0.7%, which is lower than previously reported. About 98.5% of SCCC patients have poorly or undifferentiated histology. Therefore, it is important to distinguish SCCC from poorly differentiated cervical cancer.

No prospective data was available to compare surgery with primary radiotherapy for resectable SCCC. Chen *et al*. previously reported a lower locoregional failure rate in patients who received primary radiotherapy than those who had primary surgery in stage I-II SCCC (6% vs. 27%, *P* = 0.009) \[[@R15]\]. Cohen *et al*. found that the OS (38.2% vs. 23.8%) was improved in patients who received radical hysterectomy (68.1% and 26.7% of patients underwent surgery in stage I-IIA and IIB-IVA diseases, respectively) \[[@R8]\]. In our previous study, we have found that radical surgery was the effective treatment for stage I-II SCCC \[[@R16]\]. In the present study, patients receiving surgery ± radiotherapy had better survival than those treated with primary radiotherapy. This difference may be partially explained that patients receiving surgery are usually diagnosed with stage I-II SCCC and those undergoing primary radiotherapy are often diagnosed as stage III-IV SCCC. Although surgery remains an important modality for early stage SCCC, chemotherapy-dominant comprehensive therapy is considered the main treatment for patients with advanced SCCC \[[@R3], [@R4]\].

In this study, FIGO stage was also significantly related to survival of SCCC patients. Several studies have found that patients with advanced stage were associated with poor survival \[[@R11], [@R17]--[@R19]\]. A total of 37.9% of patients had stage IV disease at the initial diagnosis in this study. In other studies, 4.6--23.5% of patients had stage IV SCCC at the initial diagnosis \[[@R6], [@R11], [@R20]\]. The discrepancy in the proportion of patients with stage IV SCCC might be ascribed to the sample size. A worse survival outcome was also associated with increasing age on multivariate analysis. In patients with non-specific pathological type of cervical cancer, the poor prognoses associated with increasing age have been reported in our previous studies \[[@R21], [@R22]\]. However, age had no significant prognostic value in other studies with SCCC subtype \[[@R8], [@R9], [@R11], [@R23]\].

It has been reported that the incidence of lymph nodes metastasis vary from 39.4% to 70% of SCCC patients who receive lymph node resection \[[@R9], [@R11], [@R23]\], which was significantly higher than that in patients with squamous cell carcinoma and adenocarcinoma of the cervix \[[@R24], [@R25]\]. However, the prognostic role of nodal status in SCCC remains controversial. We found that 52.3% of SCCC patients had node-positive, and univariate analysis indicated that patients with positive lymph nodes had a poorer prognosis. However, multivariate analysis failed to identify lymph node status as a prognostic factor. Our findings were consistent with two retrospective studies by Liao *et al*. (n = 293) \[[@R23]\] and Wang *et al*. (n = 179) \[[@R11]\] with a relatively large number of patients. Therefore, more studies are warranted in the future to assess the prognostic value of lymph node status in SCCC patients.

The treatment modalities of SCCC and small-cell lung cancer are similar due to similar biological behavior including lymph node involvement, vascular invasion, and early recurrence \[[@R26]--[@R28]\]. Chemotherapy is an important component of multimodality therapy. Several studies have found that concurrent chemotherapy or adjuvant chemotherapy improved survival in SCCC \[[@R7], [@R8], [@R15], [@R29], [@R30]\]. In this study, we cannot analyze the effect of chemotherapy on the survival of SCCC patients due to the limitations of SEER database. The British Columbia Cancer Agency began using multimodality regimen including platinum-based chemotherapy in the treatment of SCCC in 1989 \[[@R7]\]. Several studies also showed that most of patients received multimodality therapeutic strategies including chemotherapy regimens after 1990 \[[@R11], [@R17], [@R29], [@R30]\]. We included patients between 1988 and 2012, who were in a chemotherapy-based treatment era, and the survival rates of different FIGO stage in our study were similar to those of previous studies \[[@R11], [@R17], [@R29], [@R30]\]. The SEER-Medicare database contains the chemotherapy data. However, only patients with 65 years or older were included in the SEER-Medicare database, which will significantly reduce the sample size and limit the generalizability of the study (101 patients older than 65 years in the present study).

The pathological factors including surgery margin, lymphovascular invasion and parametrial invasion are the prognostic factors of cervical cancer. SEER program also lacks the information of the above pathological factors. The prognostic value of above pathological factors in SCCC remains controversial. A study be Wang *et al*. showed that positive surgical margins was an adverse prognostic factor for failure-free survival (*P* \< 0.001) but not in cancer-specific survival (*P* = 0.593), lymphovascular invasion and parametrial extension had no effect of survival in multivariate analyses \[[@R11]\]. However, the other two studies did not report the prognostic value of surgical margin on survival \[[@R9], [@R15]\]. Lymphovascular invasion and parametrial involvement were also found to have no prognostic value in SCCC \[[@R8], [@R15], [@R23]\]. Therefore, there were different prognostic factors in SCCC compared to squamous cell carcinoma and adenocarcinoma of the uterine cervix.

There are several limitations of this study. The first is the inherent biases existing in any retrospective study. However, the major strength of the present study is the ability to describe the epidemiology, clinicopathological features, treatment trends, and survival outcomes of this rare disease using a population-based study. Second, SEER database lack of information about centralized pathologic review, pathological factors (margin status, lymphovascular invasion, and parametrial invasion), details of radiation therapy and chemotherapy, and the data of local and distant recurrence. In addition, there is little information available to guide the choice of treatment in certain patients. Although prospective studies have a greater scientific impact than retrospective studies, prospective data on the outcome of different local treatment modalities in SCCC was not available.

In conclusion, SCCC is a rare disease with aggressive characteristics and prone to metastasize and is dismal in prognosis. Reduced survival was associated with increasing age, advanced stage, and treatment by primary radiotherapy. More studies are needed to confirm our results and develop optimal management of SCCC.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Data were obtained using SEER\*Stat software (Version 8.2.1; available at <http://www.seer.cancer.gov/seerstat>) from the current SEER database, which is maintained by the National Cancer Institute and consists of 18 population-based cancer registries. We included SCCC patients from 1988 to 2012 and permission to access research data files was obtained \[[@R31]\]. The tumors were classified based on their primary site of presentation using the International Classification of Disease for Oncology, Third Edition. Data released from the SEER program did not require informed patient consent and this study was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University and the Sun Yat-Sen University Cancer Center.

Demographic and clinicopathological variables {#s4_2}
---------------------------------------------

The following demographic and clinicopathological variables were collected from the SEER program: age, race, marital status, tumor grade, tumor size, FIGO stage, SEER stage, lymph node status, and local treatment modalities. Vital status and underlying cause of death were also were recorded.

Statistical analysis {#s4_3}
--------------------

The chi-square test and Fisher exact probability tests were used to evaluate the differences between qualitative data. Univariate and multivariate Cox proportional hazards model were used to identify prognostic factors predictive of CSS and OS. Multivariable analyses were used to identify independent prognostic factors that were significantly related to CSS and OS in univariate analyses. CSS and OS were calculated using the Kaplan-Meier method and compared using the log-rank test. The SPSS statistical software package, version 21.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. A value of *P* \< 0.05 was considered to be statistically significant.
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